1-benzamido-3-methylurea | 50369-40-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-benzamido-3-methylurea
• 英文别名: 3-(Methylurido)benzamide
• CAS: 50369-40-9
• 化学式: C₉H₁₁N₃O₂
• mdl: MFCD00830766
• 分子量: 193.205
• InChiKey: UTYJKGRLETYZPF-UHFFFAOYSA-N

物化性质

• 熔点：
  181 °C
• 密度：
  1.199±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  70.2
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-benzamido-3-methylurea 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 47.0h， 生成 3H-1,2,4-Triazol-3-one, 2,4-dihydro-2-ethyl-4-methyl-5-phenyl-
  参考文献：
  名称：

  The Bis(tricyclohexylstannyl) Sulfide Thionation of 3H-1,2,4- Triazol-3-ones

  摘要：

  使用双(三环己基锡)硫醚/三氯化硼组合，5-芳基-2,4-二烷基-2,4-二氢-3H-1,2,4-三唑-3-酮可以以55-74%的产率转化为相应的3H-1,2,4-三唑-3-硫酮。

  DOI：

  10.1055/s-1987-28119
• 作为产物：
  描述：

  苯甲酰肼 在 氯仿 、 异氰酸甲酯 、 苯 作用下， 生成 1-benzamido-3-methylurea
  参考文献：
  名称：

  Pacilly, Recueil des Travaux Chimiques des Pays-Bas, 1936, vol. 55, p. 101,116

  摘要：

  DOI：

文献信息

• [EN] PYRIDOPYRIMIDINES AND METHODS OF THEIR USE<br/>[FR] PYRIDOPYRIMIDINES ET LEURS MÉTHODES D'UTILISATION
  申请人：YUMANITY THERAPEUTICS INC

  公开号：WO2021247859A1

  公开（公告）日：2021-12-09

  Disclosed are compounds useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases.

  本文披露了在治疗神经系统疾病中有用的化合物。这些化合物可以单独或与其他药理活性剂结合使用，用于治疗或预防神经系统疾病。
• KINASE INHIBITORS AND USES THEREOF
  申请人：Raeppel Stephane

  公开号：US20080255155A1

  公开（公告）日：2008-10-16

  This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds, compositions and methods for the inhibition of kinase activity. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及抑制蛋白酪氨酸激酶活性的化合物。具体而言，本发明涉及抑制激酶活性的化合物、组合物和方法。本发明还提供用于治疗细胞增殖性疾病和病症的化合物、组合物和方法。
• INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY
  申请人：MethylGene Inc.

  公开号：US20130165477A1

  公开（公告）日：2013-06-27

  This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及抑制蛋白酪氨酸激酶活性的化合物。特别是，本发明涉及抑制生长因子受体蛋白酪氨酸激酶活性的化合物，从而抑制受体信号传导，例如抑制VEGF受体信号和HGF受体信号的传导。更具体地，本发明涉及用于抑制VEGF受体信号和HGF受体信号的化合物、组合物和方法。本发明还提供了用于治疗细胞增殖性疾病和病状的组合物和方法。
• Novel Inhibitors of Acetyl- and Butyrylcholinesterase Derived from Benzohydrazides: Synthesis, Evaluation and Docking Study
  作者：Neto-Honorius Houngbedji、Šárka Štěpánková、Václav Pflégr、Katarína Svrčková、Markéta Švarcová、Jarmila Vinšová、Martin Krátký

  DOI：10.3390/ph16020172

  日期：——

  tridecylamine. The compounds were evaluated for the inhibition of AChE and BChE using Ellman’s spectrophotometric method. Most of the derivatives showed the dual inhibition of both enzymes with IC50 values of 44–100 µM for AChE and from 22 µM for BChE. In general, the carboxamides inhibited AChE more strongly. A large number of the compounds showed better or quite comparable inhibition of cholinesterases

  根据之前的报道，新型2-苯甲酰肼-1-甲酰胺被设计为乙酰胆碱酯酶（AChE）和丁酰胆碱酯酶（BChE）的潜在抑制剂。这些酶的抑制剂有许多临床应用。以市售或自制的酰肼和异氰酸酯为原料，通过三种方法制备了N-甲基或十三烷基修饰的2-（取代苯甲酰基）肼-1-甲酰胺。对于甲基衍生物，使用N-琥珀酰亚胺基N-甲基氨基甲酸酯或通过Curtius重排制备异氰酸甲酯。通过库尔蒂斯重排或由三光气和十三胺再次合成十三烷基异氰酸酯。使用埃尔曼分光光度法评估化合物对 AChE 和 BChE 的抑制作用。大多数衍生物表现出对两种酶的双重抑制作用，AChE 的 IC50 值为 44–100 µM，BChE 的 IC50 值为 22 µM。一般来说，甲酰胺类药物对 AChE 的抑制作用更强。许多化合物在体外表现出比卡巴拉汀更好或相当相当的胆碱酯酶抑制作用。进行分子对接以研究化合物的可能构象及其与目标酶的相互作用。在 AChE
• 2,4-Dihydro-3H-1,2,4-triazol-3-ones as anticonvulsant agents
  作者：John M. Kane、Bruce M. Baron、Mark W. Dudley、Stephen M. Sorensen、Michael A. Staeger、Francis P. Miller

  DOI：10.1021/jm00172a015

  日期：1990.10

  A series of 5-aryl-2,4-dihydro-3H-1,2,4-triazol-3-ones was evaluated for anticonvulsant activity. In general the members of this series were prepared by the alkaline cyclization of 1-aroyl-4-alkylsemicarbazides. The resulting 2-unsubstituted 3H-1,2,4-triazol-3-ones were then alkylated, yielding 2,4-dialkyl-3H-1,2,4-triazol-3-ones. Approximately one-third of the compounds examined exhibited activity against both maximal electroshock- and pentylenetetrazole-induced seizures in mice. Receptor-binding studies suggest that this activity was not a consequence of activity at either benzodiazepine or NMDA-type glutamate receptors. From this series, compound 45 was selected for further evaluation where it was also found to be active against 3-mercaptopropionic acid, bicuculline, and quinolinic acid induced seizures in mice. In addition, 45 also protected gerbils from hippocampal neuronal degeneration produced by either hypoxia or intrastriatal quinolinic acid injection.